CAR-T cell therapy for recurrent glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have glioblastoma (WHO grade 4) that has come back after first-line treatment with surgery, radiation, and temozolomide chemotherapy.
- Your tumor must test positive for a marker called B7H3.
- You must be able to care for yourself (Karnofsky score of 60 or higher) and have a life expectancy of at least 12 weeks.
- You must have adequate blood counts, liver, kidney, and heart function.
- You cannot have had certain prior treatments like other CAR-T cells, oncolytic viruses, or carmustine wafers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD276 found on glioblastoma cells. It's for people whose glioblastoma has come back or not responded to standard treatments, and who have no other good options left.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Hear when a new Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.